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Background Cancer patients are at increased risk for depression compared with individuals with no cancer diagnosis, yet few 
interventions target depressed cancer patients.
 Methods Efficacy of psychotherapeutic and pharmacologic interventions for depression in cancer patients who met an 
entry threshold for depressive symptoms was examined by meta-analysis. Five electronic databases were sys-
tematically reviewed to identify randomized controlled trials meeting the selection criteria. Effect sizes were cal-
culated using Hedges’ g and were pooled to compare pre- and postrandomization depressive symptoms with 
a random effects model. Subgroup analyses tested moderators of effect sizes, such as comparison of different 
intervention modalities, with a mixed effects model. All statistical tests were two-sided.
 Results Ten randomized controlled trials (six psychotherapeutic and four pharmacologic studies) met the selection cri-
teria; 1362 participants with mixed cancer types and stages had been randomly assigned to treatment groups. 
One outlier trial was removed from analyses. The random effects model showed interventions to be superior 
to control conditions on reducing depressive symptoms postintervention (Hedges’ g = 0.43, 95% confidence 
interval = 0.30 to 0.56, P < .001). In the four psychotherapeutic trials with follow-up assessment, interventions 
were more effective than control conditions up to 12–18 months after patients were randomly assigned to 
treatment groups (P < .001). Although each approach was more effective than the control conditions in improv-
ing depressive symptoms (P < .001), subgroup analyses showed that cognitive behavioral therapy appeared 
more effective than problem-solving therapy (P = .01), but not more effective than pharmacologic intervention 
(P = .07).
 Conclusions Our findings suggest that psychological and pharmacologic approaches can be targeted productively toward 
cancer patients with elevated depressive symptoms. Research is needed to maximize effectiveness, accessibility, 
and integration into clinical care of interventions for depressed cancer patients.
  J Natl Cancer Inst 
By the year 2005, nearly 500 unique studies, 63% of which involved 
randomized designs, constituted the knowledge base on the efficacy 
of psychosocial interventions for individuals diagnosed with cancer 
(1). This literature often targets multiple outcomes, such as quality 
of life, distress, physical symptoms, and fatigue (1). Dramatically 
fewer trials assess depression as a primary outcome, although it is 
one of the most disabling psychological conditions experienced by 
cancer patients. Still fewer trials target the subgroup of individuals 
most in need of an intervention: those who have elevated depressive 
symptoms or are clinically depressed. The primary goal of this 
meta-analysis is to examine randomized controlled trials (RCTs) 
testing the efficacy of psychotherapeutic and pharmacologic 
interventions for depressive symptoms in individuals who are 
diagnosed with cancer and meet an entry threshold for elevated 
depressive symptoms.
Risk for depression among the population after a cancer diag-
nosis is higher compared with the population with no diagnosis 
(2), and prevalence of major depression diagnosed via standardized 
interview is estimated to be approximately 16% (3). Depression not 
only represents a psychological burden for adults with cancer but 
also carries negative health and behavioral consequences, including 
nonadherence to medical regimens (4), increased emergency and 
inpatient service use (5), delayed return to work (6), and possibly 
elevated rates of suicidal ideation or suicide (7–10) and mortality 
(10–17). In light of the pervasive impact of depression, it is essen-
tial to investigate whether published interventions are effective 
in reducing depression among cancer patients and to determine 
which approaches are most promising.
Reviewers of the literature on interventions designed to improve 
quality of life, including depression, in individuals diagnosed with 
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cancer have drawn inconsistent conclusions regarding the efficacy 
of interventions (18–30). However, most interventions include par-
ticipants regardless of their baseline standing on the outcome of 
interest. For example, one review of 60 psychosocial interventions 
for depressive symptoms or anxiety in cancer patients revealed 
that only 5% of studies restricted eligibility to patients meeting a 
specified threshold for distress (24). Individuals with low depres-
sive symptoms at baseline might not be likely to benefit from 
interventions (29,31,32), in that their outcome assessment con-
tains little room for improvement (although prevention of future 
depressive symptoms and benefit on other outcomes are possible). 
Combining trials that do and do not use an eligibility criterion for 
depression may underestimate intervention efficacy for individu-
als in most need of an intervention. Specifically selecting trials for 
cancer patients with elevated depressive symptoms or diagnosed 
depression, Rodin et al. (33) conducted a systematic review of 11 
interventions. They found “limited evidence for the effectiveness 
of pharmacological and psychosocial interventions in the treatment 
of cancer patients with depressive disorders” (33).
To our knowledge, no previously published review has included 
a quantitative analysis of the efficacy of psychosocial and pharma-
cologic approaches for individuals diagnosed with cancer who meet 
entry criteria for elevated depressive symptoms. Our review identi-
fies existing interventions that can be productively directed toward 
depressed cancer patients, illuminates limitations in the current lit-
erature, and proposes directions for research and clinical practice. 
In addition to estimating the efficacy of extant interventions and 
the duration of the effects through a meta-analysis, we examined 
whether efficacy varies as a function of therapeutic approach (ie, 
specific psychotherapy and pharmacotherapy). We also considered 
other potential moderators including characteristics of the sam-
ples, cancer, interventions, and trial quality by pooling relevant data 
from the trials that met the eligibility criteria.
Methods
Literature Search Strategy
MEDLINE, PsycINFO, CINAHL, EMBASE, and Cochrane 
Library databases were systematically searched using appro-
priate controlled-vocabulary terms specific to each database 
(Supplementary methods, available online) and keyword searching 
for terms indicating depression and frequently used assessments 
of depressive symptoms (such as depression, depressive disorder, 
Beck Depression Inventory); cancer (including neoplasm, cancer, 
leukemia); and intervention trials (including random, placebo, 
treatment). The searches were inclusive of studies published in 
English from each database’s inception through October 31, 2011. 
We also examined the references of the articles identified through 
the searches and relevant reviews and meta-analyses. We did not 
include three of the studies included in the systematic review by 
Rodin et al. (33) because two studies (34,35) did not include an 
eligibility criterion for depressive symptoms and one (36) was not 
a randomized trial.
Article Selection Strategy
Four pairs of raters (S. Hart, M. Hoyt, M. Diefenbach, D. Anderson, 
K. Kilbourn, L. Craft, J. Steel, A. Stanton) reviewed unique entries 
from database searches. Each rater reviewed the abstract indepen-
dently, and articles were obtained when the pairs agreed that the 
article required full-text examination; discrepancies were resolved 
by a third rater. Rater pairs conducted full-text review of the result-
ing articles for the following eligibility criteria: 1) adult participants 
(18 years or older) with a cancer diagnosis at the time of study 
entry; 2) inclusion criterion of elevated depressive symptoms at the 
time of study entry, as defined by each author, including specified 
threshold on a questionnaire or interview assessment; 3) random 
assignment to one or more interventions vs a usual care, placebo, 
attention control, or waiting-list control condition; and 4) depres-
sive symptoms assessed as an outcome. Any RCT that included a 
psychosocial/behavioral intervention such as cognitive behavioral 
therapy (CBT), physical activity, and/or pharmacologic component 
qualified for inclusion, including collaborative care and comple-
mentary approaches such as mind–body approaches.
Five trials employing mixed eligibility thresholds in which 
presence of depressive symptoms was not required [eg, depressive 
symptoms and/or smoking and/or problem drinking (37); depres-
sive symptoms and/or anxiety (38,39) and/or fatigue (40); depres-
sive symptoms and pain (41)] did not qualify for inclusion. Also, 
eight trials that compared two interventions in the absence of a 
control condition were not included (42–49).
Article Review Strategy
Using an online coding program designed for this project, the 
aforementioned four pairs of raters independently coded selected 
trials. Data regarding characteristics of the sample, intervention, 
and instrumentation were extracted, as were continuous data from 
assessments of depressive symptoms (percentage of participants 
meeting author-defined criteria for categorical “responder” or 
“remitted” were not extracted), to calculate effect sizes. The 
program produced a list of discrepancies, which were then 
systematically resolved by consensus, and final data were entered 
for each study. Studies were assessed for quality using a modified 
14-item version of the PEDro scale (50), which was designed 
to identify studies that are generalizable, internally valid, and 
interpretable. The modified coding scheme was identical to the 
11-item scale (50, http://www.pedro.org.au/english/downloads/
pedro-scale/), with three additional items. Two items assessed 
quality of treatment fidelity (use of a treatment manual, monitoring 
of treatment implementation), as recommended by the Treatment 
Fidelity Workgroup of the National Institutes of Health Behavior 
Change Consortium (51). The third item assessed provision of 
loss to follow-up information, included as an important quality 
indicator in other reviews of interventions for cancer patients (26). 
When published articles did not present sufficient data to calculate 
the effect sizes, we contacted authors for the required information.
Statistical Analysis
Comprehensive Meta-Analysis (version 2.2.055, Biostat, 
Englewood, NJ) was used to calculate effect sizes and analyze data 
(52). Hedges’ g was calculated for each trial and the overall pool of 
trials and was used as a measure of the effect size. Hedges’ g is cal-
culated on the basis of the standardized mean difference effect size, 
which uses the pooled within-groups SD but corrects for bias from 
small sample sizes and therefore is considered to be more accurate 
 at V
rije Universiteit, Library on July 6, 2012
http://jnci.oxfordjournals.org/
D
ow
nloaded from
 
JNCI | Articles Page 3 of 15jnci.oxfordjournals.org
than the standardized effect size typically measured by Cohen’s d 
(53). Hedges’ g is a conservative estimate of effect size, which typi-
cally is interpreted by Cohen’s d (54) guidelines (small effect = 0.20, 
medium effect = 0.50, large effect = 0.80). A positive effect size indi-
cates that the intervention was superior to the control condition in 
reducing depressive symptoms, whereas a negative effect size indi-
cates that the control condition outperformed the intervention. For 
example, a Hedges’ g of 0.50 would indicate that the intervention 
condition produced a reduction in depressive symptoms of half a 
standard deviation more than did the control condition.
When outcome data for more than one measure of depressive 
symptoms were reported in a given study (a violation of outcome 
independence), we used the mean of the effect sizes (55). A variety 
of approaches exist to examine multiple assessments of the same 
construct, including multivariable approaches (56). We used the 
commonly employed method of combining effect sizes for multiple 
outcomes, which tends to yield a more conservative effect size estimate 
than do multivariable approaches (55,57). This was applicable for four 
studies (58–61). Two separate effect sizes were calculated for trials con-
taining two intervention groups (59,62,63), in light of the observation 
that the two active treatments differed substantially in approach or 
content, such as two different medications or CBT vs social support.
Individual effect sizes were pooled in the Comprehensive Meta-
Analysis program and were calculated separately for prerandomi-
zation compared with postintervention outcomes. The assessment 
closest in time to completion of the intervention was used for calcu-
lation of posttreatment effect size. Effect sizes were also calculated 
for prerandomization to longer-term follow-up assessment, when 
follow-up assessments were reported. Because none of the stud-
ies reported the correlation between baseline and postintervention 
outcomes, we used a fixed correlation of 0.90 for within-group 
comparison. This approach has a small chance of overestimating 
effect size and has been used in earlier psychological intervention 
research examining improvement rates (64).
Variability was assumed to be caused by both sampling error and 
random differences; therefore, the data were fit to a random effects 
model, which provides more conservative estimates than a fixed 
effects model (65). A random effects estimate assumes additional 
variance beyond the set of studies and facilitates generalizability of 
results. We examined the distribution of effect sizes to identify any 
extreme values for possible elimination from analyses (66).
We identified several a priori moderators, of which the pri-
mary one involved a comparison of specific psychotherapeutic and 
pharmacologic approaches. Others included PEDro trial quality 
criteria, sample and cancer characteristics (ie, sociodemographics, 
cancer type, cancer stage, time elapsed since diagnosis), question-
naire vs interview assessment approach, and intervention character-
istics, such as length, group vs individual, and type of control group. 
Examination of any moderator required that it must be represented 
in a minimum of two trials, have sufficient variability across studies 
(note that the majority of PEDro criteria showed little variability 
across studies), and contain sufficient descriptive data for mean-
ingful analysis. The subgroup analyses used a mixed effects model, 
which pools studies within subgroups with a random effects model, 
but tested for statistically significant between-groups differences 
with a fixed effects model. A Bonferroni correction was used to 
control for inflation of Type I error when multiple between-groups 
comparisons were conducted. To test homogeneity of variance of 
the different effect sizes, we used the Q test statistic (66), which 
indicates whether the variability in effect sizes is within the range 
that would be expected if all studies shared a common population 
effect size. We also examined the I2 statistic, which ranges between 
0% and 100% and indicates the proportion of the total variance 
accounted for by heterogeneity (larger percentages reflect greater 
heterogeneity). We calculated 95% confidence intervals (CI) around 
I2 (67), using the noncentral χ2-based approach within the heterogi 
module for Stata (68). For continuous moderators, such as mean 
age, we used meta-regression techniques in the Comprehensive 
Meta-Analysis program, using the method of moments estimator.
To evaluate sources of bias, we created and examined a funnel 
plot, which graphically displays the measure of study effect size 
against sample size. A funnel plot displaying absent publication bias 
should result in a symmetrical inverted funnel-shaped graph. We 
also used Duval and Tweedie’s (69) trim and fill procedure, which 
“trims” off the asymmetric outlying part of the funnel plot, the 
remainder of which is used to estimate the true center of the plot. 
The procedure calculates the number of missing studies and pro-
vides an estimate of what the effect size would have been without 
bias, on the basis of “filling in” or imputing missing studies. Egger’s 
test of the intercept, a linear regression method, was used to further 
capture the bias in the funnel plot (70). The fail-safe N also was 
calculated to determine the number of non–statistically significant 
trials missing from the analysis that would, if included, reduce the 
observed effect size to a non–statistically significant level.
results
Selection of RCTs
A search of the five databases identified 7,770 unique studies, of 
which the rater pairs conducted full-text review of 350 articles 
(Figure 1). Fourteen unique trials and one report of a follow-up 
analysis met all inclusion criteria. Five reports included sufficient 
data to calculate effect size (58–60,63,71), and five authors provided 
additional data that included pre- and all postintervention means, 
SDs, and sample sizes separated based on the treatment arm 
(61,62,72–75). Therefore, 10 unique trials (six psychotherapeutic 
and four pharmacologic) that included a total of 1362 participants 
with mixed cancer types and stages who had been randomly assigned 
to treatment groups were included in the meta-analysis (Figure 1). 
For the remaining four articles, including two publications from 
one trial, the authors were unable to provide essential data (76–79).
Description of the Sample of RCTs
Table 1 provides demographic and cancer-related data for the 10 
trials from which patient data were included in the meta-analysis. 
Of the 10 trials, seven enrolled outpatients with mixed cancer types 
and stages. The time elapsed after cancer diagnosis ranged widely 
from 6 or fewer weeks to 7 years.
Across the six psychotherapeutic trials, 1273 eligible adult 
cancer patients were invited to take part, of whom 1000 (78%) were 
randomly assigned to treatment arms and 725 (72.5%) completed 
the postintervention assessment (Table 1). Most participants were 
women (76%; not weighted by sample size) and on average were 51 
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years of age. The education level and racial/ethnic composition of 
the included patients varied widely.
Only one of the four pharmacologic trials reported the number 
of adults invited to participate (Table 1). A total of 362 participants 
were randomly assigned to treatment arms, and 224 (62%) com-
pleted the postintervention assessment. Participants were mostly 
women (83%) and had an average age of 55 years. These reports did 
not provide sufficient data on education level, and only two studies 
reported data on race/ethnicity (>80% of patients were white).
Table 2 displays recruitment and intervention characteristics. 
Five of the six psychotherapeutic trials used systematic screening, 
which included screening of consecutive potentially eligible 
patients attending clinic to identify participants. Four trials 
evaluated a form of problem-solving therapy (PST, three of these 
within a collaborative care or multimodal approach that included 
antidepressant medication as an option), and two trials administered 
CBT. All studies except one used an individual intervention 
delivery approach (group delivery in 59), which ranged from 4 to 
10 sessions, with the exception that participants in the study by 
Ell et al. (73,75) had access to up to 1 year of collaborative care. 
Interventionists were trained psychologists or psychology graduate 
students, social workers, nurses, oncologists, or psychiatrists. Usual 
7,700 studies identified through 
MEDLINE, PsycInfo, CINAHL, 
EMBASE, and Cochrane Library 
database search (duplicates removed)
350 full-text articles reviewed
4 studies did not report sufficient data for effect size 
computation
14 trials (15 published reports) selected 
for preliminary inclusion in meta-
analyses
10 studies included in quantitative 
analyses
7,350 studies did not meet inclusion criteria upon initial 
screening of abstracts (mean % calculated from rater pairs):
1) not empirical research on adults (18+ years) with
a cancer diagnosis (53% of eliminated entries)
2) no random assignment to a psychosocial/behavioral
and/or pharmacologic intervention (including collaborative
care and complementary approaches)
(43% of eliminated entries)
3) no measure of depressive symptoms as a study
outcome (4% of eliminated entries)
335 studies did not meet inclusion criteria upon 
full-text review
1) no entry criterion of elevated depressive
symptoms only (73% of eliminated entries)
2) no usual care or other control condition
(27% of eliminated entries)
1 study excluded as extreme statistical outlier
9 studies included in meta-analysis
11 effect sizes calculated for intervention 
vs control comparison
Figure 1. Flow chart of study identification by systematic literature review.
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care, enhanced usual care (eg, usual care plus written educational 
or resource information), or a waiting list for treatment constituted 
the control conditions.
The goal of the four pharmacologic trials was to evaluate the 
efficacy of various antidepressant medications against a pill placebo 
(Table 2). Only one trial reported that screening was systematic 
(71). Pharmacologic interventions ranged in duration from 4 to 12 
weeks.
Table 3 summarizes how depression was defined and assessed. 
Studies most often employed validated questionnaire and/or 
interview assessments to assess both eligibility and outcomes. 
Postintervention assessments ranged from 8 weeks to 12 months 
after random assignment to treatment arms in psychotherapeutic 
trials and 28 days to 12 weeks in pharmacologic trials. Of the 10 
trials, only four psychotherapeutic trials included a follow-up 
assessment, which ranged from 6 to 24 months. Baseline levels of 
depressive symptoms typically ranged from mild to moderate for 
psychotherapeutic and pharmacologic trials, depending on the out-
come measure used.
Table 4 displays coding of the PEDro criteria, including qual-
ity of randomization procedures, methods of blinding, reporting of 
data, data analysis, treatment fidelity, and adequacy of follow-up. 
Trials met 9–12 of the 14 quality criteria. One trial (63) did not 
meet the allocation concealment criterion. Two trials (62,71) did 
not have groups similar at baseline on prognostic indicators, such 
as cancer stage. As is standard in these trials, no psychotherapeutic 
Table 2. Recruitment and intervention characteristics of studies included in the meta-analysis
Author, publication  
date (reference)
Recruitment 
method
Intervention  
type
Delivery 
format
Intervention 
length
Total time or 
daily dose per 
intervention 
protocol*
Type of 
therapist
Control 
intervention
Psychotherapeutic trials
Dwight-Johnson  
et al., 2005 (72)
Systematic 
screening
PST or medication  
in collaborative  
care
Individual 8 sessions 
PST or 8 wk 
medication
NR Social worker 
and 
oncologist/
psychiatrist
Usual care
Ell et al., 2008; 2011 
(73,75)
Systematic 
screening
PST and/or  
medication  
in collaborative 
care
Individual Access up to 12 
mo
NR Social worker 
and 
psychiatrist
Enhanced usual 
care
Evans and Connis,  
1995 (59)
Systematic 
screening
CBT, social support Group 8 sessions 480 min Social worker Offered crisis 
consultation 
and individual 
therapy (only 
2 participants 
elected a 
single crisis 
consultation)
Nezu et al., 2003 (63) Nonsystematic 
screening
PST, PST with  
significant  
other
Individual 10 sessions 900 min Psychology 
graduate 
students 
and social 
workers
Wait-list
Savard et al.,  
2006 (61)
Systematic 
screening
CBT Individual 8 sessions 480–720 min Psychologist Wait-list
Strong et al.,  
2008 (74)
Systematic 
screening
Education,  
problem  
solving, and 
medication
Individual 10 sessions 450 min Nurse Usual care
Pharmacologic trials
Costa et al., 1985 (58) NR Mianserin Individual 4 wk 60 mg NR Placebo pill
Fisch et al., 2003 (71) Systematic 
screening
Fluoxetine Individual, 
by mail 
delivery
12 wk 20 mg NR Placebo pill
Musselman et al.,  
2006 (62)
NR Desipramine or  
paroxetine
Individual 6 wk 125–200 mg 
desipramine; 
20–40 mg 
paroxetine
NR Placebo pill
Razavi et al., 1996 (60) NR Fluoxetine NR 5 wk (first wk 
was placebo)
20 mg NR Placebo pill
*  Medication dosage is daily goal dose after phase-in period; in some instances, goal dosages were modified according to therapeutic effect. CBT = cognitive 
behavioral therapy; NR = not reported; PST = problem-solving therapy.
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Table 3. Depression assessments and baseline depression severity
Author, publication  
date (reference) Screening criterion
Timing of 
assessments Report type
Assessment 
instrument
Mean depression score at 
baseline assessment (SD)
Psychotherapeutic trials
Dwight-Johnson et al.,  
2005 (72)
From PHQ-9/PRIME-MD, major 
depressive disorder, dysthymia,  
or persistent (baseline and  
1 mo later) depressive  
symptoms 
Baseline,  
4 mo, 8 mo
Self-report PHQ-9 PST = 12.60 (7.00); control = 
13.40 (7.20)
Ell et al., 2008; 2011  
(73,75)
On PHQ-9, one of two cardinal  
symptoms of depression for  
more than half the days to  
nearly every day and score ≥10  
on PHQ-9 and/or two DSM-IV  
questions for dysthymia
Baseline,  
12 mo, 18  
mo, 24 mo*
Self-report PHQ-9 PST = 13.17 (4.50); control = 
12.79 (4.40)
Evans and Connis,  
1995 (59)
≥16 on CES-D Baseline, 8 wk, 
6 mo
Self-report CES-D CBT = 27.20 (8.80); social  
support = 27.90 (8.40); 
control = 29.00 (7.00)
Self-report SCL-90-R  
Depression
CBT = 1.80 (0.50); social sup-
port = 1.40 (0.70); control = 
1.30 (0.70)
Nezu et al., 2003 (63) ≥14 on HAM-D and T-score ≥63  
on Global Severity Index of Brief 
Symptom Inventory
Baseline,  
10 wk†
Clinician-rated HAM-D PST = 20.40 (4.21); PST with 
significant other = 21.28 
(3.66); control = 21.23 (3.33)
Savard et al., 2006 (61) ≥7 on HADS or ≥15 on BDI Baseline,  
8 wk‡
Self-report HADS CBT = 9.42 (2.43); control = 
8.87 (2.60)
Self-report BDI CBT = 21.13 (5.41); control = 
20.40 (5.76)
Clinician-rated HAM-D CBT = 14.21 (4.26); control = 
14.40 (4.52)
Strong et al., 2008 (74) ≥15 on HADS and SCID major  
depressive disorder of ≥1 mo  
and ≥1.75 on SCL-20 Depression
Baseline,  
3 mo, 6 mo,  
12 mo
Self-report SCL-20  
Depression
PST/education = 2.40 (0.45); 
control = 2.34 (0.45)
Pharmacologic trials
Costa et al., 1985 (58) 1) Depression diagnosis according  
to Stewart et al. (1965) and  
Kathol and Petty (1981) criteria;  
2) depression succeeding or  
paralleling development of  
cancer; 3) ≥41 ZSRDS; and 4)  
≥16 HAM-D (first 17 items)
Baseline, 28 
days§
Clinician-rated CGI-S Mianserin = 3.33 (1.19);  
control = 3.32 (1.09)
Clinician-rated HAM-D Mianserin = 20.60 (3.62); 
control = 20.80 (3.85)
Self-report ZSRDS Mianserin = 50.10 (6.31); 
control = 51.20 (6.56)
Fisch et al., 2003 (71) ≥2 on Two-Question Screening  
Survey (author-developed to 
 assess depressed mood and 
anhedonia)
Baseline,  
12 wk||
Self-report Brief ZSRDS Fluoxetine = 24.44 (6.56); 
control = 23.09 (5.91)
Musselman et al.,  
2006 (62)
Clinical diagnosis of major  
depressive disorder for ≥1 mo  
assessed by DSM-III-R criteria  
and ≥14 HAM-D (1st 17 items)
Baseline,  
6 wk
Clinician-rated HAM-D¶ Desipramine = 23.00 (6.16); 
paroxetine = 21.00 (5.66); 
control = 23.91 (4.99)
Razavi et al., 1996 (60) HADS ≥13 before and after 1 wk  
on placebo; DSM-III-R major 
depressive disorder or  
adjustment disorder with 
depressed mood or mixed  
features
Baseline,  
5 wk
Self-report HADS Fluoxetine = 22.70 (6.00); 
control = 23.50 (5.50)
Clinician-rated MADRS Fluoxetine = 26.10 (7.10); 
control = 25.20 (7.70)
Self-report SCL-90-R  
Depression
Fluoxetine = 1.60 (0.70);  
control = 1.60 (0.80)
* Assessments were also conducted at 6 months, which was before completion of the intervention. BDI = Beck Depression Inventory; CBT = cognitive behavioral 
therapy; CES-D = Center for Epidemiologic Studies Depression Scale; CGI-S = Clinical Global Impression-Severity; DSM = Diagnostic and Statistical Manual; HADS 
= Hospital Anxiety and Depression Scale; HAM-D = Hamilton Rating Scale for Depression (also abbreviated as HRSD); MADRS = Montgomery-Asberg Depression 
Rating Scale; PHQ-9 = Patient Health Questionnaire; PRIME-MD = Primary Care Evaluation of Mental Disorders; PST = problem-solving therapy; SCID = Structured 
Clinical Interview for DSM Disorders; SCL = Symptom Checklist; ZSRDS = Zung Self-Rating Depression Scale.
† Assessments were also conducted at 6 and 12 months, but participants in the waitlist control were no longer assessed.
‡ Assessments were also conducted at 20 and 32 weeks, but participants in the treatment and wait-list groups were combined for analysis.
§ Assessments were also conducted at days 7, 14, and 21 after study enrollment, which was before completion of the intervention.
|| Assessments were also conducted at three other posttreatment points before 12 weeks.
¶ The CGI-S was also used to assess depression in this trial; however, data were not available from the author.
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trial blinded treatment allocation for subjects or therapists. Two 
trials did not report blinding treatment allocation for assessors 
(59,60). Three studies had measures of key outcomes on more than 
85% of participants (59,63,74). Five trials did not report having a 
treatment manual (58–60,62,71). Two trials did not report moni-
toring of treatment implementation (59,60).
Table 4. Summary of quality of the studies included in the meta-analysis
Modified Physiotherapy 
Evidence Database (PEDro) 
criterion
Author, publication date (reference)*
Psychotherapeutic trials Pharmacologic trials
Dwight-
Johnson et al., 
2005 (72)
Ell et al., 
2008; 2011 
(73,75)
Evans & 
Connis, 
1995 (59)
Nezu 
et al., 
2003 (63)
Savard 
et al., 
2006 (61)
Strong et 
al., 2008 
(74)
Costa 
et al., 
1985 (58)
Fisch 
et al., 
2003 (71)
Musselman 
et al., 2006 
(62)
Razavi 
et al., 
1996 (60)
Eligibility criteria were specified Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Subjects were randomly 
assigned to treatment groups
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Allocation was concealed Yes Yes Yes No Yes Yes Yes Yes Yes Yes
The groups were similar at base-
line regarding most important 
prognostic indicators
Yes Yes Yes Yes Yes Yes Yes No† No Yes
All participants were blinded to 
treatment
No No No No No No Yes Yes Yes Yes
There was blinding of all thera-
pists who administered the 
therapy‡
No No No No No No Yes Yes Yes Yes
All assessors who measured 
at least one key outcome 
were blinded to treatment 
information
Yes Yes No Yes Yes Yes Yes Yes Yes No
Measures of at least one key 
outcome were obtained 
from more than 85% of the 
subjects initially allocated to 
treatment groups
No No Yes Yes No Yes No No No No
All participants for whom 
outcome measures were 
available received the treat-
ment or control intervention 
as allocated or, when this was 
not done, data for at least one 
key outcome was analyzed by 
“intention to treat” (including 
imputation)
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
The results of between-group 
statistical comparisons were 
reported for at least one key 
outcome
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
The study provided both point 
measures and measures of 
variability for at least one key 
outcome§
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
The study had an adequate  
treatment fidelity protocol, 
including manualized treatment||
Yes Yes No Yes Yes Yes No No No No
The study had an adequate  
treatment fidelity protocol, 
including monitoring of  
treatment implementation
Yes Yes No Yes Yes Yes Yes Yes Yes No
Loss to follow-up information 
was provided
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Total no. of above criteria met 11 11 9 11 11 12 12 11 11 10
* “Yes” indicates that the criterion was evidenced in the article, whereas “No” indicates that the criterion is not evidenced, not applicable, not coded, or could not be 
determined in the article.
† Baseline group differences were controlled statistically.
‡ This criterion typically is not applicable to psychotherapeutic and other behavioral interventions.
§ Data were provided in the article or obtained directly from the authors.
|| Data were not coded for pharmacologic interventions.
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Effect of Intervention Compared With Control Conditions
All 10 studies (with 13 comparisons of active treatment against 
the control condition after taking into account two interven-
tion groups in three trials) reported posttest intervention effects 
against a control group. As displayed in Table 5, the random 
effects model showed that intervention conditions produced sta-
tistically significant reductions in depressive symptoms compared 
with control conditions [Hedges’ g = 1.01, 95% CI = 0.48 to 1.54, 
P < .001]. Heterogeneity was very high (I2 = 93.4%, 95% CI = 
90.0 to 95.0; Q = 181.1, degrees of freedom [df] = 12, P < .001). 
Examination of the effect sizes for outliers indicated that the two 
comparisons by Nezu et al. (63) produced very large effects for 
PST (Hedges’ g = 3.57, 95% CI = 2.90 to 4.23, P < .001) and 
PST with involvement of a significant other (Hedges’ g = 4.32, 
Figure 2. Forest plot of effect sizes (Hedges’ g, designated g in the figure) for trials included in the meta-analysis (58–62,72–75). The correspond-
ing 95% CI (designated “Lower” and “Upper” and indicated graphically by whisker bars) are also given. Effect sizes for the trials containing two 
intervention groups are displayed separately (59,62). CBT = cognitive behavioral therapy; CI = confidence interval; D = desipramine; P = paroxetine; 
SS = social support.
Figure 3. Funnel plot of standard error by Hedges’ g for trials included in the meta-analysis. The open circles represent observed studies and the 
filled circles represent imputed studies. The open diamond represents the observed effect size. The closed diamond represents the imputed effect 
size from Duval and Tweedie’s (69) trim and fill procedure. Egger’s test of the intercept indicated bias in the funnel plots was not statistically signifi-
cant (P = .16).
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95% CI = 3.55 to 5.08, P < .001), both of which were dramati-
cally larger than those of other studies (Table 5). A common rec-
ommendation for handling outliers is to remove them from the 
effect size distribution (66); eliminating that trial changed the 
overall effect size considerably, and the random effects model 
revealed a smaller effect. This model indicated that active treat-
ments produced statistically significant reductions in depressive 
symptoms compared with control conditions; heterogeneity was 
not statistically significant (Hedges’ g = 0.43, 95% CI = 0.30 to 
0.56, P < 0.001; I2 = 0%, 95% CI = 0.0 to 60.0; Q = 8.67, df = 10, 
P = .56) (Table 5). Consequently, that trial was removed from fur-
ther analyses. Figure 2 displays the forest plot for the remaining 
nine trials. As noted earlier, four studies used more than one out-
come measure, and two studies had more than one intervention 
group (one of which also reported multiple outcomes). Table 5 
shows that using only the lowest reported effect size for each of 
these studies did not substantially influence the statistically sig-
nificant effect on depressive symptoms (Hedges’ g = 0.36, 95% 
CI = 0.22 to 0.49, P < .001), as was true when the analysis was 
limited to the highest reported effect size (Hedges’ g = 0.50, 95% 
CI = 0.31 to 0.70, P < .001).
Postintervention Compared With Follow-up Assessments
Four trials (all psychotherapeutic) provided information on dura-
tion of the intervention effects (59,72–75). Three trials (59,72,74), 
provided follow-up data 6–8 months postrandomization, and 
Strong et al. (74) also included 12-month follow-up. The fourth 
trial (73,75) had follow-up at 18 and 24 months after random 
assignment to treatment arms. Because two trials had more than 
one follow-up and Ell et al. (73,75) conducted a longer follow-up, 
we performed analyses in three ways (Table 5).
First, the three trials with follow-up at 6–8 months (59,72,74) 
produced statistically significantly greater reductions in depres-
sive symptoms than did the control conditions postinterven-
tion (Hedges’ g = 0.54, 95% CI = 0.27 to 0.82, P < .001) and 
at 6–8 months (Hedges’ g = 0.56, 95% CI = 0.34 to 0.78, P < 
.001). Second, the two trials that provided data at 12–18 months 
(73–75) demonstrated statistically significantly greater reduc-
tions in depressive symptoms favoring intervention vs control 
conditions (Hedges’ g = 0.34, 95% CI = 0.16 to 0.53, P < .001 at 
postintervention; Hedges’ g = 0.37, 95% CI = 0.18 to 0.55, P < 
.001 at 12–18 months). For the trial that had 24-month follow-up 
(75), the intervention was effective postintervention (Hedges’ g = 
0.26, 95% CI = 0.02 to 0.51, P = .04), but not at 24 months after 
random assignment (Hedges’ g = 0.19, 95% CI = 20.08 to 0.46, 
P = .17).
Subgroup Analyses
Effects of CBT vs PST vs pharmacologic interventions were 
assessed. For the psychotherapeutic studies, we created subgroups 
on the basis of the theoretical approach employed: CBT (59,61) 
vs PST (delivered within a collaborative care model or a multi-
modal intervention approach) (72–75). We then performed a sub-
group comparison for CBT vs PST vs pharmacologic interventions 
(Table 5). CBT, PST, and pharmacologic interventions were more 
effective than control conditions in reducing depressive symptoms, 
as indicated by statistically significant effect sizes for each compari-
son (Hedges’ g = 0.83, 95% CI = 0.48 to 1.18, P < .001; Hedges’ g 
= 0.33, 95% CI = 0.15 to 0.50, P <.001; Hedges’ g = 0.44, 95% CI 
= 0.19 to 0.68, P < .001, respectively). The difference among the 
three groups was statistically significant (P = .04). Post hoc analyses 
revealed a statistically significant difference between CBT and PST 
(P = .01), but the difference was not statistically significant between 
CBT and pharmacologic interventions (P = .07) or between PST 
and pharmacologic interventions (P = .48). The difference between 
CBT vs PST remained statistically significant after a Bonferroni 
correction for multiple tests (P = .02).
Table 5. Effects of intervention compared with control conditions 
and subgroup meta-analyses
Study or subgroup Hedges’ g* (95% CI) P
Effect of intervention vs control conditions   
 All included trials (58–63,71–75)† 1.01 (0.48 to 1.54) <.001
 Included trials (58–62,71–75)‡; outlier 
trial (63) removed§
0.43 (0.30 to 0.56) <.001
 Included trials (58–62,71–75) using 
lowest reported effect size
0.36 (0.22 to 0.49) <.001
 Included trials (58–62,71–75) using 
highest reported effect size
0.50 (0.31 to 0.70) <.001
Effect of intervention compared with 
control conditions postintervention and 
at follow-up assessments
  
 Included trials with 6–8 mos 
postrandomization follow-up 
assessments (59,72,74)
  
  Postintervention 0.54 (0.27 to 0.82) <.001
  Follow-up 0.56 (0.34 to 0.78) <.001
 Included trials with 12–18 mos 
postrandomization follow-up 
assessments (73–75)
  
  Postintervention 0.34 (0.16 to 0.53) <.001
  Follow-up 0.37 (0.18 to 0.55) <.001
 Included trial with 24 mos postrandomi-
zation follow-up assessments (75)
  
  Postintervention 0.26 (0.02 to 0.51) .040
  Follow-up 0.19 (-0.08 to 0.46) .173
Subgroup analyses
Effect of CBT vs PST vs pharmacologic 
interventions
  
 CBT(59,61) 0.83 (0.48 to 1.18) <.001
 PST (72–75) 0.33 (0.15 to 0.50) <.001
 Pharmacologic (58,60,62,71) 0.44 (0.19 to 0.68) <.001
Effect of intervention in psychotherapeutic 
trials meeting PEDro criterion: Whether 
at least 85% of study participants had 
postintervention data available for 
analysis
  
 Criterion met (59,74) 0.58 (0.34 to 0.81) <.001
 Criterion not met (61,72,73) 0.31 (0.10 to 0.52) .004
* Hedges’ g was calculated on the basis of the standardized mean difference 
effect size which uses the pooled within-groups SD. Subgroup analyses 
used a mixed effects model, which pools studies within subgroups with a 
random effects model, but tested for statistically significant between-groups 
differences with a fixed effects model. All P values are two-tailed. CBT = 
cognitive behavioral therapy; PST = problem-solving therapy.
† Heterogeneity: I2 = 93.4%, 95% CI = 90.0 to 95.0; Q = 181.1, degrees of 
freedom (df) = 12, P < .001.
‡ Heterogeneity: I2 = 0%, 95% CI = 0.0 to 60.0; Q = 8.67, df = 10, P = .56.
§ Comparisons from Nezu et al. (63) included examination of effects of PST 
(Hedges’ g = 3.57, 95% CI = 2.90 to 4.23, P < .001) and PST with involvement 
of a significant other (Hedges’ g = 4.32, 95% CI = 3.55 to 5.08, P < .001).
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The only PEDro criterion that had sufficient variability for 
analysis was whether at least 85% of study participants had postin-
tervention outcome data available for analysis (Table 4). Of the 
psychotherapeutic studies, two met this criterion (59,74) and dem-
onstrated a statistically significant reduction in depressive symp-
toms for active compared with control conditions (Hedges’ g = 
0.58, 95% CI = 0.34 to 0.81, P < .001) (Table 5). The three studies 
that did not meet this criterion (61,72,73) also produced a statisti-
cally significant improvement in depressive symptoms (Hedges’ g 
= 0.31, 95% CI = 0.10 to 0.52, P = .004) (Table 5). The two effect 
sizes were similar (P = .10). Note that none of the pharmacologic 
trials met this criterion.
None of the continuous variables examined through metare-
gression were statistically significantly associated with the observed 
overall effect size. Specifically, age (P = .91), percentage of female 
participants (P = .13), the number of psychotherapeutic sessions (P 
= .98), and the number of weeks on medication (P = .93) were not 
statistically significantly associated with the effect of active treat-
ment on depressive symptoms as determined by the method of 
moments estimator (Supplementary Table 1, available online).
Publication Bias
The funnel plot (Figure 3) shows a generally even distribution of 
effect sizes by standard errors, but the right side of the plot was 
populated by an additional two studies, compared with the left side. 
The slight skewness on the right side was confirmed by the fact 
that Duval and Tweedie’s (69) trim and fill procedure imputed two 
studies on the left side of the plot, which indicates slight publica-
tion bias. As shown in Figure 3, the two studies that were imputed 
using the procedures described in the statistical analysis section 
slightly reduced the overall effect size (Hedges’ g = 0.39). However, 
the 95% CI of 0.24 to 0.54 for this effect size did not include 0. 
Egger’s test of the intercept was not statistically significant (P = .16) 
for bias in the funnel plot. The fail-safe N (the number of unpub-
lished studies reporting statistically nonsignificant results needed 
to reduce the observed effect to statistical nonsignificance) of 106 
confirms the relative stability of the observed effect size.
Discussion
This meta-analysis of RCTs reveals that the set of five psychothera-
peutic (after removal of one outlier) and four pharmacologic inter-
ventions were reliably superior in reducing depressive symptoms 
relative to control conditions for adults diagnosed with cancer who 
met an eligibility threshold for elevated depressive symptoms. The 
statistically significant effect size across trials was moderate and 
indicated that post-treatment, depressive symptoms were slightly 
less than a half SD lower for adults in intervention groups com-
pared with those who were assigned to control treatment. In the 
four psychotherapeutic trials that included a longer-term follow-up 
(ie, 6–24 months postrandomization; note that the interventions 
were of variable length), the follow-up effect sizes remained sta-
tistically significant up to 12–18 months after randomization (P < 
.001), indicating sustained effects.
The effect size obtained in this meta-analysis is somewhat 
lower than that found in a meta-analysis of interventions for adults 
who met an entry criterion for depression but were not selected 
for diagnosis of a medical disorder (80) and is comparable to that 
of a meta-analysis (81) of 15 RCTs of psychological interventions 
in patients who had elevated depressive symptoms and had been 
diagnosed with one of 10 different medical disorders, including 
four oncology samples (d = .42 after two outliers with very large 
effect sizes were removed). Previous meta-analyses (23,27,29) 
have documented the efficacy of psychotherapeutic interventions 
for cancer patients unselected at study entry for depression, par-
ticularly for individuals with relatively high baseline depressive 
symptoms (31,32,82). For example, Schneider et al. (31) con-
ducted a meta-analysis of 27 psychosocial interventions (12 RCTs; 
15 single-group designs) for cancer patients to examine whether 
preintervention depressive symptoms, as assessed by the Hospital 
Anxiety and Depression Scale (83), moderated intervention effi-
cacy. Effects on HADS depressive symptoms were negligible 
when baseline depressive symptoms were low and pronounced 
when symptoms were relatively high. This finding did not vary 
by study design or intervention type, setting, or dose, and it held 
both immediately after treatment and 2–7 months later, although 
it weakened at longer follow-up. Baseline depressive symptoms 
explained 51.5% of the variance in treatment efficacy on depressive 
symptoms. Randomized and single-group interventions that spe-
cifically selected participants for elevated distress produced larger 
effect sizes than did nonselective interventions, but this factor was 
not a unique moderator of outcomes after statistical control for 
baseline depressive symptoms.
Our findings advance this literature by demonstrating that 
psychological and pharmacologic approaches, evaluated in RCTs, 
can be targeted productively toward cancer patients in need of 
intervention by virtue of clinical depression or elevated depressive 
symptoms. Whether tailoring or targeting of interventions to be 
responsive to specific characteristics of depression in the context 
of cancer, such as depression history or perceived cancer-related 
losses, produces more potent effects requires study.
In the current meta-analysis, heterogeneity of effect sizes 
was not marked across trials, and subgroup analyses suggest that 
effects did not vary systematically as a function of trial attrition 
rate, participant age and sex, or intervention length. However, a 
comparison of CBT, PST, and pharmacologic approaches revealed 
that CBT produced statistically significantly larger effects than did 
PST and a somewhat but statistically nonsignificantly larger effect 
than pharmacologic interventions; PST and pharmacologic inter-
ventions were similar. It is important to note that these compari-
sons are not equivalent to comparing the different interventions 
directly within an RCT. Thus, the finding of the superiority of 
CBT must be interpreted cautiously and within the context of the 
specific trials (Tables 1–4). In addition to their distinct interven-
tion content, the CBT trials also differ from the other approaches 
in that the CBT trials on average included somewhat fewer par-
ticipants, arguably employed less stringent eligibility criteria for 
depressive symptoms, and had less elapsed time from baseline to 
postintervention assessment compared with PST (but not with 
pharmacologic trials). In addition, CBT was the sole therapeutic 
approach of those trials, whereas PST was administered within a 
collaborative care (72,73,75) or multimodal approach (74), which 
included a pharmacologic option and did not invariably include 
PST (72,73,75). Furthermore, although interventionists received 
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systematic training in PST, they did not necessarily have a back-
ground in delivering psychological treatments (74), whereas inter-
ventionists in the CBT trials were experienced in that modality. 
These last two points also suggest the importance of continued 
research on the effectiveness of psychosocial interventions deliv-
ered within a specialized psycho-oncology context vs an approach 
imported from integrated primary care (84–86).
It is also important to note that the outlier removed from anal-
ysis was a PST trial that yielded very large effect sizes (63). We 
could not definitively identify why this trial yielded extremely large 
effects. However, it differed from the other RCTs in that it was con-
ducted by founders of the treatment approach, provided intensive 
training of therapists on the manualized protocol, involved weekly 
supervision provided by the founders, used recruitment of inter-
ested patients rather than systematic screening of a clinic or other 
population, and required as an eligibility criterion that a significant 
other be willing to participate in the intervention, all of which may 
have contributed to the outlying large effect sizes. The advantage 
of CBT compared with other approaches to treat depression in the 
general population has been suggested in other reviews (87,88); 
however, randomized trials are required to test its advantage over 
other treatments in depressed cancer patients. Although head-to-
head comparisons of intervention approaches are accruing, none of 
the 10 trials identified in our literature search compared the same 
two interventions (42–45,47–49,59,62,63). In the most relevant 
trial (47), a form of PST was compared with behavioral activation 
treatment in breast cancer patients with major depression. Both 
interventions were effective in decreasing depressive symptoms, 
with gains maintained or augmented throughout 12 months.
Several limitations of this meta-analysis and the current lit-
erature are apparent. First, three trials could not be included in 
the analysis because of incomplete data, and it is possible that 
some trials were missed, even in this comprehensive search. The 
finding that more than 100 trials—each demonstrating no statis-
tically significant reduction in depression for the intervention (vs 
control condition)—would be needed to nullify the statistically 
significant effect of intervention, however, suggests the effect’s 
stability. Nonetheless, the observation that only ten trials were 
available for analysis highlights the paucity of interventions tar-
geted to cancer patients with elevated depressive symptoms and 
points to the importance of conducting additional RCTs. Second, 
differences among trials were pronounced on some features, 
including sample size, participants’ education level, gender, race/
ethnicity, cancer stage, and time elapsed after cancer diagnosis, 
interventionist type and expertise, intervention length, and entry 
criteria for and operationalization of depression. Although sta-
tistically significant heterogeneity in effect sizes was not evi-
dent once the one outlier was removed, a larger pool of trials 
might yield important moderators of intervention effects. Third, 
relatively few intervention approaches were represented in this 
review; approaches receiving current attention in cancer popu-
lations, such as physical activity interventions, require study for 
their impact on depression. Finally, generalizability of the find-
ings to other groups (eg, adolescents/young adults) awaits addi-
tional research.
Limitations in the individual trials also suggest that additional 
research is essential. Specifically, five trials relied on questionnaire 
assessment of depressive symptoms rather than interview-based 
assessment for depressive disorder, medication protocols were no 
longer than 12 weeks in duration, attrition from the point of ran-
dom assignment to the postintervention assessment exceeded 33% 
in four of 10 trials (62,71–73), and six trials did not include follow-
up assessment beyond the postintervention point.
The current meta-analysis revealed reliable positive effects of 
psychotherapeutic and pharmacologic interventions, with some 
advantage for CBT, for adults diagnosed with cancer who had 
comorbid elevated depressive symptoms or a depression diagno-
sis. These data are consonant with findings from the literature on 
depression in the general adult population showing that bona-fide 
psychotherapies and second-generation antidepressants are effec-
tive at reducing depression in the short term (89). Our findings 
inform two crucial clinical questions, the first of which regards 
the advisability of screening for depression in cancer patients and 
subsequent provision of interventions specifically targeted toward 
individuals with elevated symptoms. A recent meta-analysis (31) 
suggests that preintervention assessment of distress may be an effi-
cient way to identify those who are most likely to benefit from ther-
apeutic intervention. Further, the National Comprehensive Cancer 
Network guidelines (90) and an Institute of Medicine report (91) 
emphasize the importance of screening cancer patients for distress. 
Reviews indicate that screening for depression has not yet become 
a standard part of oncology care (92,93), however, and controversy 
exists regarding the utility of psychosocial screening in oncology 
settings (94–97). Our findings demonstrate that when assessment 
is performed with psychometrically sound questionnaires or inter-
views and intervention is targeted toward cancer patients meeting 
criteria for elevated depressive symptoms, reliable improvement in 
depression occurs, at least within a research context. The available 
evidence suggests that patients who demonstrate elevated symp-
toms of depression should be referred for treatment. However, two 
caveats are important. First, because screening itself was not rand-
omized in these trials, we can conclude that only the combination 
of depression assessment and intervention (not screening by itself) 
is effective. Indeed, authors of a recent review reported that no 
RCTs have examined whether screening for depression in cancer 
patients improves depression outcomes and outweighs the poten-
tial harms of such screening (98). Second, dissemination research 
on the effectiveness of interventions for depressed cancer patients 
in clinical settings is lacking.
In light of the efficacy of existing interventions demonstrated 
in this meta-analysis, a second question is whether additional 
interventions require development and investigation for individu-
als with cancer who are depressed. Burgeoning awareness of the 
importance of depression in individuals with cancer is evidenced by 
on-going trials of interventions targeted at this group (99,100). We 
would argue that such intervention development and evaluation 
in RCTs remains essential for several reasons. First, conclusions 
regarding intervention efficacy are limited by the small number 
of existing trials and their lack of efficacy assessment beyond 3 
months for pharmacologic trials and 24 months after randomiza-
tion for psychotherapeutic trials. Second, examination of important 
moderators of efficacy was limited by the small number of avail-
able trials. For example, insufficient data were available to exam-
ine whether interventions are differentially effective for depressed 
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individuals with advanced cancers vs early-stage disease. A particu-
larly interesting question is whether interventions require tailoring 
to individuals who have a premorbid history of depression (101) 
and to individuals who develop depression at particular points in 
the cancer trajectory (eg, at diagnosis and medical treatment, after 
treatment completion, at cancer recurrence; 102,103). Third, the 
obtained moderate effect size leaves room for improvement in the 
power of interventions to ameliorate depression. Finally, interven-
tions that are maximally accessible to diverse groups require study. 
Most interventions in the present review were delivered in person 
in individual sessions, which requires substantial resources on the 
part of both recipients and professionals. In light of the psychologi-
cal, behavioral, and economic toll of depression, as well as its health 
burden on adults with cancer, intensive attention to the develop-
ment and dissemination of maximally effective, efficient, and acces-
sible interventions for heterogeneous cancer patients is warranted.
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